Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06528496 · ClinicalTrials.gov registry record · Phase 2
N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma
A Phase 2 study of Neuroblastoma and High-risk Neuroblastoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
- 1
- Study location
NCT06528496: Recruiting Phase 2 study of Neuroblastoma and High-risk Neuroblastoma, sponsored by Memorial Sloan Kettering Cancer Center.
NCT06528496 is a Phase 2 study of Neuroblastoma and High-risk Neuroblastoma that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 45 participants, below the 238-participant average among 94 other Neuroblastoma trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06528496, a Phase 2 study of Neuroblastoma and High-risk Neuroblastoma, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to find out whether N10 chemotherapy is a safe and effective treatment for children with high-risk neuroblastoma.
Primary Outcome
To assess the early Complete Response/CR rate in newly-diagnosed HR-NB patients.
Conditions Studied
Interventions
- DRUG Vincristine
- DRUG Cytoxan
- DRUG Topotecan
- BIOLOGICAL DANYELZA
- BIOLOGICAL Sargramostim
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2024-07-22 |
| Est. Completion | 2029-07-22 |
| Phase | Phase 2 |
What NCT06528496 shows while recruiting
NCT06528496 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 238-participant average among 94 other Neuroblastoma trials with a reported enrollment target (81% lower).
The record links to 3 conditions, with Neuroblastoma appearing as the primary indexed condition, and to 5 interventions - of which Vincristine is the first listed.
NCT06528496 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06528496 about?
NCT06528496 is a clinical study titled "N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma". The purpose of this study is to find out whether N10 chemotherapy is a safe and effective treatment for children with high-risk neuroblastoma.
What is the current status of trial NCT06528496?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2024-07-22. Estimated completion is 2029-07-22.
What conditions does trial NCT06528496 study?
This clinical trial studies the following conditions: Neuroblastoma, High-risk Neuroblastoma, Childhood Neuroblastoma.
What interventions are being tested in trial NCT06528496?
The interventions under investigation include: Vincristine (DRUG), Cytoxan (DRUG), Topotecan (DRUG), DANYELZA (BIOLOGICAL), Sargramostim (BIOLOGICAL).
Who is sponsoring clinical trial NCT06528496?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06528496 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06528496's enrollment target sits among peer trials
45 48th of 94 higher than 47 of 94 other Neuroblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neuroblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
RECRUITING · Phase 2
-
Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma
RECRUITING · Phase 2
-
A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
RECRUITING · Phase 2
-
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
RECRUITING · Phase 2
-
Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
RECRUITING · Phase 2
-
A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI